Navigation Links
BioElectronics and Pulsed Shortwave Therapy Make Progress
Date:5/23/2013

FREDERICK, Md., May 23, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very effective, safe consumer medical devices, comments on the FDA panel meeting for non-thermal shortwave diathermy:

The FDA's Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting was held on May 21, 2013 in Gaithersburg, MD, USA.  The focus of the meeting was very narrow, in that the FDA had instructed the panel to focus solely on the application of non-thermal shortwave diathermy for the treatment of postoperative pain and edema and the treatment of edema following blepharoplasty.  Industry representatives, including BioElectronics President Andy Whelan , presented a compelling case for reclassification.  The recommendation from the FDA's advisory panel was reclassification from Class III to Class II with special controls including a requirement for new clinical data. At this time it is not clear if the requirement for new clinical data applies to existing products.  The FDA will make a final decision on the recommendations of the panel in due course, though BioElectronics believes that the FDA will follow the panel's recommendations.

"Overall, we see the advisory panel and the FDA's recommendations as a positive and potentially significant development," stated Ian Rawe , BioElectronics Director of Clinical Research.  "After decades of use and research, the FDA now believes that the available evidence suggests that shortwave devices can be safely regulated. If existing cleared devices are compelled to submit new clinical data, our 3rd Molar Extraction clinical study at Tufts Dental School, Boston, meets all the FDA's clinical research standards. This study is evaluating both postoperative pain and edema, with edema being quantified with a 3D digital imaging system (http://www.3dmd.com/). Therefore, because of these expected developments and with expanded clinical research in place we are confident of moving forward."

We also continue to press our Petitions in the FDA's Commissioner's Office of Science Integrity for our musculoskeletal and menstrual pain market clearances and we are optimistic that this reclassification concession will help expedite market clearances. 

About BioElectronics Corporation

BioElectronics (www.bielcorp.com) is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care.

Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com

 

 

 


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Presents FDA Reclassification Panel
2. BioElectronics New Patent Published
3. BioElectronics to Ease pain in Iraq
4. BioElectronics Selects New South Korean Distributor for its Healing and Pain Products
5. BioElectronics Obtains Additional US Patent For Its Unique Pain Devices
6. BioElectronics Enters Malaysias Pain Relief Market
7. BioElectronics Unique Pain Relief Product Featured on Leading Healthcare Show in Spain
8. BioElectronics Announces Chronic and Postoperative Wound Care Product Distribution in Italy
9. BioElectronics CEO Honored by Chabad at Johns Hopkins Medicine
10. BioElectronics Expands European Distribution to Malta
11. BioElectronics Announces Publication of Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... Summary GlobalData,s new report, "EU5 Glucose Monitoring Market ... EU5 Glucose Monitoring market. The report provides value, in ... prices (USD) within market segments - Blood Glucose Meters, ... also provides company shares and distribution shares data for ...
(Date:1/17/2017)... , Jan. 17, 2017 The interventional ... billion by 2021 from USD 6.35 billion in 2016, ... driving the growth of this market are rising incidence ... for minimally invasive surgeries. The global interventional ... application, and region. On the basis of type, the ...
(Date:1/17/2017)... -- The Global Nebulizers Market is poised to grow ... decade to reach approximately $1698.68 million by 2025. Some ... include rapidly growing demand in emerging regions, increasing use ... and online marketing strategies by key players. ... pneumatic nebulizers, ultrasonic nebulizers and mesh nebulizers. Pneumatic nebulizers ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... partnership with Sigfox in the U.S.A. to offer Internet of Things ... new offerings on large-scale environmental sensor deployments such as monitoring solutions used to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... companies and ranked among the top US security companies for consecutive years, today ... This announcement brings a year-long independent board nomination process to a close and ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide comfort and ... in the fast-casual category, announces a hearty and wholesome Winter Menu. Starting today, ... Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show ... Vegas, Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade ...
Breaking Medicine News(10 mins):